Long-term survival of participants in the prostate cancer prevention trial. - Test2 - elhamkhani - TriplyDB

Long-term survival of participants in the prostate cancer prevention trial.

Long-term survival of participants in the prostate cancer prevention trial.

http://www.wikidata.org/entity/Q34077860

about

The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer Molecular cancer prevention: Current status and future directions Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort Mortality is associated with inflammation, anemia, specific diseases and treatments, and molecular markers Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review).Prevention and early detection of prostate cancer.Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.Genetic variation: effect on prostate cancer.Addressing overdiagnosis and overtreatment in cancer: a prescription for change Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.Primary chemoprevention of breast cancer: Are the adverse effects too burdensome?Extracting the Benefit of Nexrutine® for Cancer Prevention.Broccoli-Derived Sulforaphane and Chemoprevention of Prostate Cancer: From Bench to Bedside.Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer Translational and clinical implications of the genetic landscape of prostate cancer.Future directions in the prevention of prostate cancer.The intriguing role of fibroblasts and c-Jun in the chemopreventive and therapeutic effect of finasteride on xenograft models of prostate cancer.Quality of Life and Sexual Health in the Aging of PCa Survivors.Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.A review of statin use and prostate cancer.Fatty Acid Synthesis Intermediates Represent Novel Noninvasive Biomarkers of Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate.Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia.Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?Cancer Prevention: Lessons Learned and Future Directions.Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer.Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.Prostate cancer trends in Asia.The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: Results and reflections.Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer.5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial.

P2860

Q24564068-A8A317D0-8E28-460F-9E42-FB69D4DF303B Q26774593-8E291472-1FEE-48E3-B1AA-010E7A88DD13 Q26782494-04FD99FA-FBEA-4B88-BC7C-D5F7EF1F5B2F Q26797207-8C9E34E5-9BCA-4D62-93DA-56E51BF1821C Q28069186-EEEB25F4-4D61-47F9-8C10-990F3ED21CBE Q28546311-38D14E6B-0E0D-4875-B659-76F2885B8B18 Q33579874-A4BA2304-69BE-414C-8F28-03591AD26911 Q33883502-F19896F5-BFE9-42FB-ACC3-7A3F1C564940 Q34005866-9084C9CE-E1E1-416F-82CF-B8318CE52E08 Q34064040-6A2DB189-B282-4D96-AAF0-9609ADBD64B5 Q34141355-0C6C8BFC-B9C2-40D7-BAC7-68F547BEB288 Q34371057-48268230-3903-4B19-B63D-1BF063731DEC Q34542518-6C1EBCB3-1F5E-4D35-A3F2-25823CBA36F5 Q34663656-E82DAC72-C0A8-4289-8718-DE2BE95D9F04 Q35067706-3E9BCB9F-A274-4BD0-B305-371A30729F2D Q35689075-E1812370-D75E-47B8-B0DF-C1288689D073 Q35744037-ECE8B5AE-C8E0-464E-9027-7F6CE086794C Q36236997-D1160004-F0A9-4859-A78A-91F569C0798D Q36255185-F7C360AA-A032-4D2D-BDEF-A4207CE3602D Q37009071-0B09E16F-325F-4162-AEA6-12133DCC33E1 Q37270512-62D95BBD-ADA5-4CB8-9481-84AE150C11DB Q37279094-5B8C4659-BB8F-44D3-9D4B-138F065A49D7 Q37414987-FEDA680E-B5A4-46F7-BC9D-BA06C8E509AC Q37686901-ADC0A86A-EF0C-44EC-B470-ADE37E4E889C Q37737611-83535CCD-CE16-4D95-BB08-E6385483440F Q38272644-36503FA7-58C3-4BC1-B912-3A018F86222A Q38375592-313274B5-1964-4073-B888-E7EAE42B8E95 Q38433368-B906C79D-E225-4A24-9A65-97B8F41794A0 Q38485721-6CF4916A-B53E-4804-B980-EB7BB5C6D708 Q38571198-DAEA7865-C08B-4498-AA40-3F740F1C77F3 Q38652183-FF620BB2-7CD7-4EE5-B07F-25561AF9DC2D Q38733910-6D8900D9-4908-4367-BC2C-DA234202EA9B Q38883820-DA2ED0BA-2EB3-412F-A10C-847C868FCA48 Q38922207-DD41D08D-7615-4EE8-A3DE-2A8FB7449E9B Q39168087-7F0C2CC8-E03F-4C37-9C82-C94C4E5BBF8C Q39374516-2DA0AC57-5972-43E7-9D43-AAE548A0E746 Q40756146-8DD9E540-E6F6-4746-B636-52CF8A306F61 Q40852349-7E73491D-E808-4616-B3F5-35E5CFEB474B Q40954634-43E1631D-B516-4F75-8353-4DCB840CFFE3 Q42070592-5103BBD5-5AC3-476C-8ABD-760771C56AF6

P2860

Long-term survival of participants in the prostate cancer prevention trial.

http://www.wikidata.org/entity/Q34077860

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Long-term survival of participants in the prostate cancer prevention trial.

@ast

Long-term survival of participants in the prostate cancer prevention trial.

@en

Long-term survival of participants in the prostate cancer prevention trial.

@nl

type

label

Long-term survival of participants in the prostate cancer prevention trial.

@ast

Long-term survival of participants in the prostate cancer prevention trial.

@en

Long-term survival of participants in the prostate cancer prevention trial.

@nl

prefLabel

Long-term survival of participants in the prostate cancer prevention trial.

@ast

Long-term survival of participants in the prostate cancer prevention trial.

@en

Long-term survival of participants in the prostate cancer prevention trial.

@nl

P1433

Q34077860-63BB5233-BE66-485E-A75D-31E6C36F7392

P1476

Q34077860-F6269E2D-BCD5-41F0-A529-FB23BAA8DC9F

P2093

Q34077860-08EDB307-AA2B-4B00-BAE2-C76BC53F1695

Q34077860-20AA7733-7084-4789-BEDC-931DF7E0A01A

Q34077860-5F598B0B-7845-4E1D-A0A4-3C47BF6B8284

Q34077860-AC5BFCFA-1513-456C-8B88-AFB0C2BA811E

Q34077860-CD56ED3F-15F6-4862-BFEA-577643584F6A

Q34077860-D6138CD2-8371-4B99-8986-D021C2EA376A

Q34077860-F2DED074-8717-4077-956D-EFDA80544DC0

Q34077860-F4C16D46-3304-4072-9620-BE4EE1109479

P2860

Q34077860-04DBF9DC-A232-4074-B738-B5A858951600

Q34077860-0E9594E5-7E68-44D2-9F51-68ACADFDD231

Q34077860-171C7674-E83F-4BEB-897C-2C4096C18F82

Q34077860-1D1B37AD-A30B-4324-8DFB-BA7651569853

Q34077860-28A7962F-D6FB-470A-96CB-7F02904B626B

Q34077860-58E6CBDF-A550-406F-8404-E8EF76E84CD7

Q34077860-6053F33F-CED6-4DF7-A949-2870911C0514

Q34077860-67AC8F3A-EF49-4C8A-816A-3D776411B3D1

Q34077860-6849ED47-72D9-4EC5-87FD-36474CB4FB85

Q34077860-8F90172A-E55B-4840-AD12-5F09AE8C4900

P304

Q34077860-3EEE435F-20EC-4E44-BC60-AD80FB728D93

P31

Q34077860-560039BE-6B6B-4679-968C-08FCE83C2795

P356

Q34077860-C0A2FDF5-864D-439E-AAEA-CB8CD584FC6D

P407

Q34077860-F82BA622-FBA2-4237-9950-EF4F11035829

P433

Q34077860-D938D7F2-7638-4F6C-985B-C7F8E9CBFCA3

P478

Q34077860-CC4800F5-2B8B-4873-8E59-7A8D9E1483EF

P577

Q34077860-9419F7D9-E2DC-42A7-A430-14E1E3E67DD4

P698

Q34077860-7D27E07D-1125-4EEF-9D97-955910F5D5B0

P932

Q34077860-950E9544-3352-4901-97C5-DB168466B010

P356

P1433

The New England Journal of Medicine

P1476

Long-term survival of participants in the prostate cancer prevention trial.

@en

P2093

Catherine M Tangen

http://www.w3.org/2001/XMLSchema#string

Howard L Parnes

http://www.w3.org/2001/XMLSchema#string

Ian M Thompson

http://www.w3.org/2001/XMLSchema#string

Leslie G Ford

http://www.w3.org/2001/XMLSchema#string

Lori M Minasian

http://www.w3.org/2001/XMLSchema#string

M Scott Lucia

http://www.w3.org/2001/XMLSchema#string

Paul A Godley

http://www.w3.org/2001/XMLSchema#string

Phyllis J Goodman

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.

Prostate-cancer mortality at 11 years of follow-up.

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

The influence of finasteride on the development of prostate cancer.

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines.

Validation of the Social Security Death Index (SSDI): An Important Readily-Available Outcomes Database for Researchers.

Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.

Long-term follow-up in cancer prevention trials (It ain't over 'til it's over).

P304

603-610

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1215932

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23944298

http://www.w3.org/2001/XMLSchema#string

P932

4141537

http://www.w3.org/2001/XMLSchema#string